APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adult and Pediatric Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adult and Pediatric Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchAdult and Pediatric Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Adult and Pediatric Vaccines Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Adult and Pediatric Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adult and Pediatric Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Adult and Pediatric Vaccines Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Adult and Pediatric Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adult and Pediatric Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adult and Pediatric Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adult and Pediatric Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adult and Pediatric Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adult and Pediatric Vaccines market include Sanofi, Johnson and Johnson, Novartis, Merck, Pfizer, GlaxoSmithKline, Sinovac Biotech, AstraZeneca and Takeda Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Adult and Pediatric Vaccines market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adult and Pediatric Vaccines and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adult and Pediatric Vaccines revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Adult and Pediatric Vaccines market.

Adult and Pediatric Vaccines Segment by Company

Sanofi

Johnson and Johnson

Novartis

Merck

Pfizer

GlaxoSmithKline

Sinovac Biotech

AstraZeneca

Takeda Pharmaceutical

LG Life Sciences

Bavarian Nordic

Adult and Pediatric Vaccines Segment by Type

Adult Vaccines

Pediatric Vaccines

Adult and Pediatric Vaccines Segment by Application

Hospitals

Medical Care Centers

Others

Adult and Pediatric Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Adult and Pediatric Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Adult and Pediatric Vaccines key companies, revenue, market share, and recent developments.

3. To split the Adult and Pediatric Vaccines breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Adult and Pediatric Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adult and Pediatric Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Adult and Pediatric Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult and Pediatric Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adult and Pediatric Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult and Pediatric Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adult and Pediatric Vaccines industry.

Chapter 3: Detailed analysis of Adult and Pediatric Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Adult and Pediatric Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Adult and Pediatric Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adult and Pediatric Vaccines Industry Trends Table 2. Adult and Pediatric Vaccines Industry Drivers Table 3. Adult and Pediatric Vaccines Industry Opportunities and Challenges Table 4. Adult and Pediatric Vaccines Industry Restraints Table 5. Global Adult and Pediatric Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adult and Pediatric Vaccines Revenue Share by Company (2021-2026) Table 7. Global Adult and Pediatric Vaccines Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Adult and Pediatric Vaccines Key Company Manufacturing Base & Headquarters Table 9. Global Adult and Pediatric Vaccines Company, Product Type & Application Table 10. Global Adult and Pediatric Vaccines Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Adult and Pediatric Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Adult Vaccines Table 15. Significant Companies of Pediatric Vaccines Table 16. Global Adult and Pediatric Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Adult and Pediatric Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Adult and Pediatric Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Adult and Pediatric Vaccines Sales Value Share by Type (2021-2026) Table 20. Global Adult and Pediatric Vaccines Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of Medical Care Centers Table 23. Significant Companies of Others Table 24. Global Adult and Pediatric Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Adult and Pediatric Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Adult and Pediatric Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Adult and Pediatric Vaccines Sales Value Share by Application (2021-2026) Table 28. Global Adult and Pediatric Vaccines Sales Value Share by Application (2027-2032) Table 29. Global Adult and Pediatric Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Adult and Pediatric Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Adult and Pediatric Vaccines Sales Value Share by Region (2021-2026) Table 32. Global Adult and Pediatric Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Adult and Pediatric Vaccines Sales Value Share by Region (2027-2032) Table 34. Global Adult and Pediatric Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Adult and Pediatric Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Adult and Pediatric Vaccines Sales Value Market Share by Country (2021-2026) Table 37. Global Adult and Pediatric Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Adult and Pediatric Vaccines Sales Value Market Share by Country (2027-2032) Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Sanofi Adult and Pediatric Vaccines Product Portfolio Table 43. Sanofi Recent Development Table 44. Johnson and Johnson Company Information Table 45. Johnson and Johnson Business Overview Table 46. Johnson and Johnson Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Johnson and Johnson Adult and Pediatric Vaccines Product Portfolio Table 48. Johnson and Johnson Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novartis Adult and Pediatric Vaccines Product Portfolio Table 53. Novartis Recent Development Table 54. Merck Company Information Table 55. Merck Business Overview Table 56. Merck Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Adult and Pediatric Vaccines Product Portfolio Table 58. Merck Recent Development Table 59. Pfizer Company Information Table 60. Pfizer Business Overview Table 61. Pfizer Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Pfizer Adult and Pediatric Vaccines Product Portfolio Table 63. Pfizer Recent Development Table 64. GlaxoSmithKline Company Information Table 65. GlaxoSmithKline Business Overview Table 66. GlaxoSmithKline Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. GlaxoSmithKline Adult and Pediatric Vaccines Product Portfolio Table 68. GlaxoSmithKline Recent Development Table 69. Sinovac Biotech Company Information Table 70. Sinovac Biotech Business Overview Table 71. Sinovac Biotech Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sinovac Biotech Adult and Pediatric Vaccines Product Portfolio Table 73. Sinovac Biotech Recent Development Table 74. AstraZeneca Company Information Table 75. AstraZeneca Business Overview Table 76. AstraZeneca Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. AstraZeneca Adult and Pediatric Vaccines Product Portfolio Table 78. AstraZeneca Recent Development Table 79. Takeda Pharmaceutical Company Information Table 80. Takeda Pharmaceutical Business Overview Table 81. Takeda Pharmaceutical Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Takeda Pharmaceutical Adult and Pediatric Vaccines Product Portfolio Table 83. Takeda Pharmaceutical Recent Development Table 84. LG Life Sciences Company Information Table 85. LG Life Sciences Business Overview Table 86. LG Life Sciences Adult and Pediatric Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. LG Life Sciences Adult and Pediatric Vaccines Product Portfolio Table 88. LG Life Sciences Recent Development Table 89. Bavarian Nordic Company Information Table 90. Bavarian Nordic Business Overview Table 91. Bavarian Nordic Adult and Pediatric Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Bavarian Nordic Adult and Pediatric Vaccines Product Portfolio Table 93. Bavarian Nordic Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Adult and Pediatric Vaccines Product Image Figure 2. Global Adult and Pediatric Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adult and Pediatric Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Adult and Pediatric Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Adult Vaccines Image Figure 8. Pediatric Vaccines Image Figure 9. Global Adult and Pediatric Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Adult and Pediatric Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Adult and Pediatric Vaccines Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. Medical Care Centers Image Figure 14. Others Image Figure 15. Global Adult and Pediatric Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Adult and Pediatric Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Adult and Pediatric Vaccines Sales Value Share by Application (2021-2032) Figure 18. Global Adult and Pediatric Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Adult and Pediatric Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Adult and Pediatric Vaccines Sales Value (2021-2032) & (US$ Million) Figure 21. North America Adult and Pediatric Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Adult and Pediatric Vaccines Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Adult and Pediatric Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Adult and Pediatric Vaccines Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Adult and Pediatric Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Adult and Pediatric Vaccines Sales Value (2021-2032) & (US$ Million) Figure 27. South America Adult and Pediatric Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Adult and Pediatric Vaccines Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Adult and Pediatric Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Adult Vaccines
  • Pediatric Vaccines
Applications
  • Hospitals
  • Medical Care Centers
  • Others
Companies covered
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Sinovac Biotech
  • AstraZeneca
  • Takeda Pharmaceutical
  • LG Life Sciences
  • Bavarian Nordic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adult and Pediatric Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adult and Pediatric Vaccines Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Adult and Pediatric Vaccines Market Dynamics
  1. 2.1 Adult and Pediatric Vaccines Industry Trends
  2. 2.2 Adult and Pediatric Vaccines Industry Drivers
  3. 2.3 Adult and Pediatric Vaccines Industry Opportunities and Challenges
  4. 2.4 Adult and Pediatric Vaccines Industry Restraints
3 Adult and Pediatric Vaccines Market by Company
  1. 3.1 Global Adult and Pediatric Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Adult and Pediatric Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Adult and Pediatric Vaccines Company Ranking (2024-2026)
  4. 3.4 Global Adult and Pediatric Vaccines Company Manufacturing Base and Headquarters
  5. 3.5 Global Adult and Pediatric Vaccines Company Product Type and Application
  6. 3.6 Global Adult and Pediatric Vaccines Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Adult and Pediatric Vaccines Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Adult and Pediatric Vaccines Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Adult and Pediatric Vaccines Market by Type
  1. 4.1 Adult and Pediatric Vaccines Type Introduction
  2. 4.1.1 Adult Vaccines
  3. 4.1.2 Pediatric Vaccines
  4. 4.2 Global Adult and Pediatric Vaccines Sales Value by Type
  5. 4.2.1 Global Adult and Pediatric Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adult and Pediatric Vaccines Sales Value by Type (2021-2032)
  7. 4.2.3 Global Adult and Pediatric Vaccines Sales Value Share by Type (2021-2032)
5 Adult and Pediatric Vaccines Market by Application
  1. 5.1 Adult and Pediatric Vaccines Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Medical Care Centers
  4. 5.1.3 Others
  5. 5.2 Global Adult and Pediatric Vaccines Sales Value by Application
  6. 5.2.1 Global Adult and Pediatric Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Adult and Pediatric Vaccines Sales Value by Application (2021-2032)
  8. 5.2.3 Global Adult and Pediatric Vaccines Sales Value Share by Application (2021-2032)
6 Adult and Pediatric Vaccines Regional Value Analysis
  1. 6.1 Global Adult and Pediatric Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adult and Pediatric Vaccines Sales Value by Region (2021-2032)
  3. 6.2.1 Global Adult and Pediatric Vaccines Sales Value by Region: 2021-2026
  4. 6.2.2 Global Adult and Pediatric Vaccines Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adult and Pediatric Vaccines Sales Value (2021-2032)
  7. 6.3.2 North America Adult and Pediatric Vaccines Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Adult and Pediatric Vaccines Sales Value (2021-2032)
  10. 6.4.2 Europe Adult and Pediatric Vaccines Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Adult and Pediatric Vaccines Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Adult and Pediatric Vaccines Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Adult and Pediatric Vaccines Sales Value (2021-2032)
  16. 6.6.2 South America Adult and Pediatric Vaccines Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Adult and Pediatric Vaccines Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Adult and Pediatric Vaccines Sales Value Share by Country, 2025 VS 2032
7 Adult and Pediatric Vaccines Country-level Value Analysis
  1. 7.1 Global Adult and Pediatric Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adult and Pediatric Vaccines Sales Value by Country (2021-2032)
  3. 7.2.1 Global Adult and Pediatric Vaccines Sales Value by Country (2021-2026)
  4. 7.2.2 Global Adult and Pediatric Vaccines Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Adult and Pediatric Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Adult and Pediatric Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Adult and Pediatric Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Adult and Pediatric Vaccines Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson and Johnson
  8. 8.2.1 Johnson and Johnson Company Information
  9. 8.2.2 Johnson and Johnson Business Overview
  10. 8.2.3 Johnson and Johnson Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson and Johnson Adult and Pediatric Vaccines Product Portfolio
  12. 8.2.5 Johnson and Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Adult and Pediatric Vaccines Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Adult and Pediatric Vaccines Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Adult and Pediatric Vaccines Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Adult and Pediatric Vaccines Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Sinovac Biotech
  38. 8.7.1 Sinovac Biotech Company Information
  39. 8.7.2 Sinovac Biotech Business Overview
  40. 8.7.3 Sinovac Biotech Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sinovac Biotech Adult and Pediatric Vaccines Product Portfolio
  42. 8.7.5 Sinovac Biotech Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Adult and Pediatric Vaccines Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Takeda Pharmaceutical
  50. 8.9.1 Takeda Pharmaceutical Company Information
  51. 8.9.2 Takeda Pharmaceutical Business Overview
  52. 8.9.3 Takeda Pharmaceutical Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Takeda Pharmaceutical Adult and Pediatric Vaccines Product Portfolio
  54. 8.9.5 Takeda Pharmaceutical Recent Developments
  55. 8.10 LG Life Sciences
  56. 8.10.1 LG Life Sciences Company Information
  57. 8.10.2 LG Life Sciences Business Overview
  58. 8.10.3 LG Life Sciences Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LG Life Sciences Adult and Pediatric Vaccines Product Portfolio
  60. 8.10.5 LG Life Sciences Recent Developments
  61. 8.11 Bavarian Nordic
  62. 8.11.1 Bavarian Nordic Company Information
  63. 8.11.2 Bavarian Nordic Business Overview
  64. 8.11.3 Bavarian Nordic Adult and Pediatric Vaccines Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bavarian Nordic Adult and Pediatric Vaccines Product Portfolio
  66. 8.11.5 Bavarian Nordic Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst